Senti Biosciences Inc ASH Annual Meeting Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Yale Jen - Laidlaw & Company Uk Ltd - Analyst : Good morning and thanks for taking the questions and congrats on a very outstanding outcome at this far, comparing to other targeted therapies in the AML space. I got two here. The first one is that, you -- do you guys start to be able to dissecting the patient's pathophysiology differences between the dose responder versus the non-responder, was that SHPC level could be a gating factor, maybe that could help design the next study? Then I have a follow-up.

Question: Yale Jen - Laidlaw & Company Uk Ltd - Analyst : Okay, great. That's very helpful. And the one more question here is that given you have the NOT gate, which preserve some of the help to fast recovery and some of the healthy cells and so do you anticipate that provide some level of benefit on the disease survival side and also just want to confirm that the, do you feel the patient probably will more go to the higher percentage of patients going to the transplant versus maybe another modality of treatment.

Question: Yale Jen - Laidlaw & Company Uk Ltd - Analyst : Okay, great. That's very helpful. And maybe just squeeze in one more question. In terms of the pivotal pivotal study you're planning on speaking with the FDA going forward, we noticed that that in other targets, the therapy, the size were ranging from somewhere between 65 patients to up to almost 200 patients. And given the scope you're therapy may be able to treat, do you have a thought, in terms of what those number might be and any other colors in terms of the potential Phase 3 study you can talk about? Thanks.

Question: Yale Jen - Laidlaw & Company Uk Ltd - Analyst : Okay, great. And again, congrats on the outcomes and I think thats it beats most of the other therapies and so far approving the space in a quite a good margins. Thanks.

Question: Geulah Livshits - Chardan Capital Markets LLC - Analyst : Good morning, and I wanted to add my congrats on the data and thanks for taking the questions. So maybe can you elaborate on any trends you're seeing with respect to any of the patient characteristics or features of the AML or features that you're seeing in the CyTOF data sets that might be starting to correlate with response or in those patients who respond and then progress with progression there? And also if you're seeing any correlation between the responses and donor material. Respect to the manufacturing of the cells, and then I have to follow-up. Thanks. LSEG STREETEVENTS | www.lseg.com | Contact Us consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies. DECEMBER 09, 2025 / 1:00PM, SNTI.OQ - Senti Biosciences Inc ASH Annual Meeting

Question: Geulah Livshits - Chardan Capital Markets LLC - Analyst : Great. And I don't know if Dr. Farhadfar is still available for questions, but I, she is, I wanted to get a sense of her perspective on how she think about the incorporating into clinical practice and what percent of AML patients that you seem to be suited for treatment with 202.

Question: Geulah Livshits - Chardan Capital Markets LLC - Analyst : Perfect. Thank you.

Question: Geulah Livshits - Chardan Capital Markets LLC - Analyst : I guess from your perspective as well, if, in terms of the percentage of patients that you think would be suitable for this type of treatment, obviously, in the context of available therapies against the different targeted mutations as well as, we've seen some additional data from some of your peers at ASH as well and to how you're thinking about that competitive landscape.

Question: Geulah Livshits - Chardan Capital Markets LLC - Analyst : Perfect. Thank you.